BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Mar 29, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Imatinib regulatory update

The U.K.'s NICE issued a preliminary appraisal for Glivec imatinib from Novartis for the adjuvant treatment of gastrointestinal stromal tumors (GISTs) after surgery. The committee requested further clarification of existing data, including revised cost-effectiveness analysis for patients at significant risk of recurrence and for the subgroups with a moderate risk...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >